交易 ACADIA Pharmaceuticals Inc - ACAD 差價合約

交易條件

• 類型: 差價合約
• 點差: 0.09
• 長倉隔夜倉息調整: -0.02157%
• 短倉隔夜倉息調整: -0.00065%
• 隔夜倉息調整時間: 22:00 (UTC)
• 貨幣: USD
• 最低成交量: 0.1
• 保證金: 50.00%
• 證券交易所: United States of America
• 交易佣金: 0%
• 保證止損溢價: 1%

主要統計數據

• 前收盤價: 22.42
• 開倉: 22.33
• 1 年變化: 21.16%
• 日區間: 21.52 - 22.33

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson''s disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.